| 2026 Consensus Statement Update | 2022 Consensus Statement |
|---|---|
| Scenario 2 Patients with a treatment-free interval of > 6 months and < 12 months after the end of adjuvant trastuzumab or trastuzumab plus pertuzumab (IV or SC) based therapy: T-DXd combined with pertuzumab is the preferred first line treatment. | NA |
References
DB-09
Quality of evidence: I; Strength of recommendation: A